122 related articles for article (PubMed ID: 2697581)
1. The Merlini, Waldenström, Jayakar staging system revisited.
Merlini G; Gobbi PG; Ascari E
Eur J Haematol Suppl; 1989; 51():105-10. PubMed ID: 2697581
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and staging in multiple myeloma: a reappraisal.
Bataille R; Durie BG; Grenier J; Sany J
J Clin Oncol; 1986 Jan; 4(1):80-7. PubMed ID: 3510284
[TBL] [Abstract][Full Text] [Related]
3. A plea to overcome the concept of "staging" and related inadequacy in multiple myeloma.
Gobbi PG; Bertoloni D; Grignani G; Pieresca C; Rossi A; Rutigliano L; Merlini G; Riccardi A; Ascari E
Eur J Haematol; 1991 Mar; 46(3):177-81. PubMed ID: 2009950
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the staging system proposed by Merlini, Waldenström and Jayakar for multiple myeloma.
Bettini R; Steidl L; Rapazzini P; Giardina G
Acta Haematol; 1983; 70(6):379-85. PubMed ID: 6417962
[TBL] [Abstract][Full Text] [Related]
5. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
6. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
7. A new staging system for multiple myeloma based on the number of S-phase plasma cells.
San Miguel JF; García-Sanz R; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
Blood; 1995 Jan; 85(2):448-55. PubMed ID: 7811998
[TBL] [Abstract][Full Text] [Related]
8. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
9. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
Greipp PR; Katzmann JA; O'Fallon WM; Kyle RA
Blood; 1988 Jul; 72(1):219-23. PubMed ID: 3291982
[TBL] [Abstract][Full Text] [Related]
10. Serum beta 2-microglobulin at remission and relapse in patients with multiple myeloma.
Brenning G; Wibell L; Bergström R
Eur J Clin Invest; 1985 Oct; 15(5):242-7. PubMed ID: 3935453
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
Mihou D; Katodritou E; Zervas K
Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.
Bataille R; Boccadoro M; Klein B; Durie B; Pileri A
Blood; 1992 Aug; 80(3):733-7. PubMed ID: 1638024
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment serum beta 2-microglobulin in multiple myeloma.
Brenning G; Simonsson B; Källander C; Ahre A
Br J Haematol; 1986 Jan; 62(1):85-93. PubMed ID: 3510657
[TBL] [Abstract][Full Text] [Related]
14. A comparison of two staging systems for myeloma.
Vercelli D; Cozzolino F; Di Guglielmo R
Nouv Rev Fr Hematol (1978); 1981; 23(2):107-10. PubMed ID: 7290984
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
16. Biochemical markers in multiple myeloma: a multivariate analysis.
Simonsson B; Källander CF; Brenning G; Killander A; Gronowitz JS; Bergström R
Br J Haematol; 1988 May; 69(1):47-53. PubMed ID: 3289607
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.
Litam P; Swan F; Cabanillas F; Tucker SL; McLaughlin P; Hagemeister FB; Rodriguez MA; Velasquez WS
Ann Intern Med; 1991 May; 114(10):855-60. PubMed ID: 2014946
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma.
Witzig TE; Gertz MA; Lust JA; Kyle RA; O'Fallon WM; Greipp PR
Blood; 1996 Sep; 88(5):1780-7. PubMed ID: 8781435
[TBL] [Abstract][Full Text] [Related]
19. [Comparative study of 2 prognostic classification systems for myeloma and examination of the correlation between initial bone marrow plasmacytosis and prognosis. A propos of a homogeneous population of 50 patients followed from diagnosis to death].
Pesce A; Cassuto JP; Grisot C; Gratecos N; Bayle J; Viot G; Dujardin P
Nouv Rev Fr Hematol (1978); 1983; 25(5):311-7. PubMed ID: 6657481
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
Scarffe JH; Anderson H; Palmer MK; Crowther D
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1361-4. PubMed ID: 6357802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
